CEO of New UK Cell And Gene Therapy Hub Says 'All Systems Are Go'
Executive Summary
CEO of the Stevenage-based center hopes the new cell and gene manufacturing hub will see a growing life sciences ecosystem coalesce around it.
You may also be interested in...
Shake It Off? Japan Mulls Routes Out Of Bioventure Doldrums
The long-recurring theme of how effectively to foster Japan’s bioventure sector again emerged as a key thread at recent major industry meeting, while the broader topic of effective partnering occupied the minds of industry and academia alike.
J.P. Morgan Notebook Day 1: Pfizer, Gilead, Alnylam, Novartis, Sarepta, Deal Trends And Cell Therapy Challenges
News and notes from the 2019 J.P. Morgan Healthcare Conference. Pfizer CEO Bourla underscores need for scientific and commercial innovation, Gilead makes M&A a priority, Novartis' new R&D chief reflects on first meeting with CEO Narasimhan, Sarepta CEO Ingram clarifies regulatory path for micro-dystrophin, J.P. Morgan outlines deal and macro biopharma trends in 2019, and cell therapy panel discusses manufacturing challenges.
J.P. Morgan Notebook Day 1: Pfizer, Gilead, Alnylam, Novartis, Sarepta, Deal Trends And Cell Therapy Challenges
News and notes from the 2019 J.P. Morgan Healthcare Conference. Pfizer CEO Bourla underscores need for scientific and commercial innovation, Gilead makes M&A a priority, Novartis' new R&D chief reflects on first meeting with CEO Narasimhan, Sarepta CEO Ingram clarifies regulatory path for micro-dystrophin, J.P. Morgan outlines deal and macro biopharma trends in 2019, and cell therapy panel discusses manufacturing challenges.